Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|August 16, 2017
Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile NeutropeniaFekade Bruck Sime, Uwe Hahn, Morgyn S Warner, et al.
Pathology|December 16, 2025
Advancing diagnostic targeted RNA sequencing for haematological malignancies within an Australian sample exchange programEric Wenlong Li, Ing-Soo Tiong, Clare Gould, et al.
Antimicrobial Agents and Chemotherapy|July 1, 2015
Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignanciesFekade Bruck Sime, Michael S Roberts, Ing Soo Tiong, et al.
The Journal of Antimicrobial Chemotherapy|May 9, 2015
Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trialFekade Bruck Sime, Michael S Roberts, Ing Soo Tiong, et al.
Oncotarget|September 9, 2017
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II studyPeter Tan, Ing Soo Tiong, Shaun Fleming, et al.
Ejhaem|November 29, 2023
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemiaSean Harrop, Phillip C Nguyen, David Byrne, et al.
Leukemia|February 17, 2026
Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasetsIng Soo Tiong, Sally Hunter, Yamuna Kankanige, et al.
Pathology|April 24, 2022
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statementAnoop K Enjeti, Rishu Agarwal, Piers Blombery, et al.
Blood Advances|January 18, 2025
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)Chong Chyn Chua, Sun Loo, Chun Yew Fong, et al.
Blood Advances|July 28, 2022
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistancePiers Blombery, Ella R Thompson, Thomas E Lew, et al.
Pageof 4